Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Immunotherapy delays type 1 diabetes mellitus in high-risk individuals

Researchers say that teplizumab potentially delaying progression to diabetes in patients who are at-risk is important, particularly in children. 

Glucose test for diabetes


Using the results of six-monthly glucose tolerance tests, researchers found that 23 (72%) of the 32 people taking placebo developed diabetes, compared with 19 (43%) of the 44 participants allocated to the teplizumab group

Certain individuals at high risk of developing type 1 diabetes mellitis (T1DM) can delay progression to clinical disease by two years or more with a two-week course of teplizumab, according to the results of a phase II study published in The New England Journal of Medicine (9 June 2019)[1].

Teplizumab, an anti-CD3 monoclonal antibody, modifies CD8+ T cells, which are thought to play a role in the destruction of insulin-producing beta cells.

Researchers enrolled 76 participants aged 8–49 years who were relatives of people with T1DM, had at least two types of diabetes-related autoantibodies and abnormal glucose tolerance.

The participants were randomly assigned to a 14-day course of teplizumab or placebo, with oral glucose tolerance tests performed every six months or until participants developed T1DM.

Of the 32 participants allocated to placebo, 23 (72%) developed diabetes, compared with 19 (43%) of the 44 participants allocated to the teplizumab group. The median time for people in the control group to develop diabetes was 24.4 months, compared with 48.4 months for those who received teplizumab.

The researchers, who were led by Kevan Herold, professor of immunobiology and medicine at Yale University, said: “The delay of progression to diabetes is of clinical importance, particularly for children, in whom the diagnosis is associated with adverse outcomes.” 

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206725

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.